The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis.

Hiroyuki ArashiJunichi YamaguchiErisa Kawada-WatanabeHisao OtsukiHaruki SekiguchiHiroshi OgawaNobuhisa Hagiwara

Published in: Journal of cardiovascular pharmacology and therapeutics (2020)

Standard lipid-lowering therapy with pitavastatin mono-therapy improved the eicosapentaenoic acid/arachidonic acid ratio for patients with ACS. Intensive lipid-lowering therapy with pitavastatin + ezetimibe did not improve the eicosapentaenoic acid/arachidonic acid ratio, although LDL-C decreased significantly. Inhibition of the improvement in the eicosapentaenoic acid/arachidonic acid ratio by adding ezetimibe may affect cardiovascular disease prognosis.

Keyphrases

cardiovascular disease
type diabetes
acute coronary syndrome
metabolic syndrome
cardiovascular events